Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine

References

• SlamonDJClarkGMWongSGLevinWJUllrichAMcGuireWLHuman breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneScience198723547851771823798106
   PubMed Web of Science ®Google Scholar
• SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med20013441178379211248153
   PubMed Web of Science ®Google Scholar
• RomondEHPerezEABryantJTrastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerN Engl J Med2005353161673168416236738
   PubMed Web of Science ®Google Scholar
• Piccart-GebhartMJProcterMLeyland-JonesBHerceptin Adjuvant (HERA) Trial Study TeamTrastuzumab after adjuvant chemotherapy in HER2-positive breast cancerN Engl J Med2005353161659167216236737
   PubMed Web of Science ®Google Scholar
• SlamonDEiermannWRobertNBreast Cancer International Research GroupAdjuvant trastuzumab in HER2-positive breast cancerN Engl J Med2011365141273128321991949
   PubMed Web of Science ®Google Scholar
• DawoodSBroglioKEstevaFJDefining prognosis for women with breast cancer and CNS metastases by HER2 statusAnn Oncol20081971242124818334512
   PubMed Web of Science ®Google Scholar
• MusolinoACiccolalloLPanebiancoMMultifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry studyCancer201111791837184621509760
   PubMed Web of Science ®Google Scholar
• GeyerCEForsterJLindquistDLapatinib plus capecitabine for HER2-positive advanced breast cancerN Engl J Med2006355262733274317192538
   PubMed Web of Science ®Google Scholar
• CameronDCaseyMPressMA phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analysesBreast Cancer Res Treat2008112353354318188694
   PubMed Web of Science ®Google Scholar
• HurvitzSAHuYO’BrienNFinnRSCurrent approaches and future directions in the treatment of HER2-positive breast cancerCancer Treat Rev201339321922922658319
   PubMed Web of Science ®Google Scholar
• JunttilaTTLiGParsonsKPhillipsGLSliwkowskiMXTrastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancerBreast Cancer Res Treat2011128234735620730488
   PubMed Web of Science ®Google Scholar
• Lewis PhillipsGDLiGDuggerDLTargeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugateCancer Res200868229280929019010901
   PubMed Web of Science ®Google Scholar
• AustinCDWenXGazzardLNelsonCSchellerRHScalesSJOxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugatesProc Natl Acad Sci U S A200510250179871799216322102
   PubMed Web of Science ®Google Scholar
• Lewis PhillipsGDLiGDuggerDLTargeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugateCancer Res200868229280929019010901
   PubMed Web of Science ®Google Scholar
• EricksonHKParkPUWiddisonWCAntibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processingCancer Res20066684426443316618769
   PubMed Web of Science ®Google Scholar
• GirishSGuptaMWangBClinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancerCancer Chemother Pharmacol20126951229124022271209
   PubMed Web of Science ®Google Scholar
• MahapatraKDarbonneWBumbacaDT-DM1-induced thrombocytopenia results from impaired platelet production in a HER2-independent mannerMol Cancer Ther201110Suppl 1A135
   Google Scholar
• ThonJNDevineMTJurak BegonjaATibbittsJItalianoJEJrHigh-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1) – mediated inhibition of platelet productionBlood2012120101975198422665936
   PubMed Web of Science ®Google Scholar
• KropIEBeeramMModiSPhase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancerJ Clin Oncol201028162698270420421541
   PubMed Web of Science ®Google Scholar
• BeeramMKropIEBurrisHAA phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancerCancer2012118235733574022648179
   PubMed Web of Science ®Google Scholar
• ModiSEALoRussoPSamantMGuardinoEAlthausBKropIEResults from a phase Ib study of trastuzumab emtansine (T-DM1), paclitaxel (T), and pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab2012 Annual Meeting of the American Society of Clinical OncologyJune 1–5, 2012Chicago, Illinois Abstract 528
   Google Scholar
• BurrisHAIIIRugoHSVukeljaSJPhase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapyJ Clin Oncol201129439840521172893
   PubMed Web of Science ®Google Scholar
• KropIELoRussoPMillerKDA phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabineJ Clin Oncol201230263234324122649126
   PubMed Web of Science ®Google Scholar
• HurvitzSADirixLKocsisJPhase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancerJ Clin Oncol20133191157116323382472
   PubMed Web of Science ®Google Scholar
• MillerKDDiérasVHarbeckNPhase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancerJ Clin Oncol201432141437144424733796
   PubMed Web of Science ®Google Scholar
• VermaSMilesDGianniLEMILIA Study GroupTrastuzumab emtansine for HER2-positive advanced breast cancerN Engl J Med2012367191783179123020162
   PubMed Web of Science ®Google Scholar
• KropIEKimSBGonzález-MartínATH3RESA study collaboratorsTrastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trialLancet Oncol201415768969924793816
   PubMed Web of Science ®Google Scholar
• PerezEAHurvitzSAAmlerLCRelationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancerBreast Cancer Res2014163R5024887458
   PubMed Web of Science ®Google Scholar
• BaselgaJVermaSRoJRelationship between tumor biomarkers (BM) and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC)Cancer Res201373Suppl 8LB-63
   Web of Science ®Google Scholar
• TakaraKSakaedaTOkumuraKAn update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapyCurr Pharm Des200612327328616454744
   PubMed Web of Science ®Google Scholar
• LiGFieldsCTParsonsKLGuoJLewis PhillipsGDTrastuzumab-DM1: mechanisms of action and mechanisms of resistanceEur J Cancer20108773
   Web of Science ®Google Scholar
• TanXJinGMyersJTumor cells selected for resistance to an antibody-drug conjugate retain sensitivity to ADCs with modified linkers and payloadsCancer Res201373Suppl 8462923722543
   PubMed Web of Science ®Google Scholar
• EngelmanJATargeting PI3K signalling in cancer: opportunities, challenges and limitationsNat Rev Cancer20099855056219629070
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas NetworkComprehensive molecular portraits of human breast tumoursNature20124907418617023000897
   PubMed Web of Science ®Google Scholar
• HankerABPfefferleADBalkoJMMutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapiesProc Natl Acad Sci U S A201311035143721437723940356
   PubMed Web of Science ®Google Scholar
• GianniLBianchiniGKiermaierANeoadjuvant Pertuzumab (P) and Trastuzumab (H): Biomarker Analyses of a 4-Arm Randomized Phase II Study (NeoSphere) in Patients (pts) with HER2–Positive Breast Cancer (BC)Cancer Res201171Suppl 24S51
   Google Scholar
• BaselgaJBradburyIEidtmannHNeoALTTO Study TeamLapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trialLancet2012379981663364022257673
   PubMed Web of Science ®Google Scholar
• BaselgaJMajewskiINuciforoPGPI3KCA mutations and correlation with pCR in the NeoALTTO trial (BIG 01–06)European Cancer Congress 2013 Abstract Book in the European Journal of Cancer2013 Abstract 1859
   Google Scholar
• GwinWR1SpectorNLPertuzumab protects the achilles’ heel of trastuzumab – emtansineClin Cancer Res201420227828024240115
   PubMed Web of Science ®Google Scholar
• PhillipsGDFieldsCTLiGDual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapyClin Cancer Res201420245646824097864
   PubMed Web of Science ®Google Scholar
• LoRussoPMWeissDGuardinoEGirishSSliwkowskiMXTrastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancerClin Cancer Res201117206437644722003071
   PubMed Web of Science ®Google Scholar